CNAT Conatus Pharmaceuticals Inc. gains 26% Jul 17, 2017

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease and raised transaminases, as well as for the treatment of patients with severe alcoholic hepatitis. The company was founded in 2005 and is headquartered in San Diego, California. http://www.priceseries.com/trade/CNAT-Conatus-Pharmaceuticals-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2017062320170717.html